Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 15/20 | 0.54 |
| ▸ | GSK3A | P49840 | 14/20 | 0.54 |
| ▸ | SYK | P43405 | 14/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593369 | 0.93 | DDR2 (0.60) | DDR2SRCGSK3ASYKMAPK14 | |
| SCHEMBL594182 | 0.90 | DDR2 (0.62) | DDR2SRCGSK3ASYKMAPK14 | |
| SCHEMBL10130496 | 0.90 | DDR2 (0.61) | DDR2SRCGSK3ASYKMAPK14 | |
| SCHEMBL593583 | 0.89 | DDR2 (0.64) | DDR2SRCGSK3ASYKMAPK14 | |
| SCHEMBL595053 | 0.89 | DDR2 (0.61) | DDR2SRCGSK3ASYKMAPK14 | |
| SCHEMBL592918 | 0.89 | DDR2 (0.61) | DDR2SRCGSK3ASYKMAPK14 | |
| SCHEMBL10130495 | 0.88 | DDR2 (0.58) | DDR2SRCGSK3ASYKMAPK14 | |
| SCHEMBL594056 | 0.88 | DDR2 (0.68) | DDR2SRCGSK3ASYKMAPK14 | |
| SCHEMBL594498 | 0.88 | DDR2 (0.60) | DDR2SRCGSK3ASYKMAPK14 | |
| SCHEMBL600408 | 0.88 | DDR2 (0.60) | DDR2SRCGSK3ASYKMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114873-B2 | 1,4-disubstituted naphthalenes as inhibitors of p38 map kinase | ARQULE, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100311754-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7829560-B2 | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase | ARQULE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080032967-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080032967-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311754-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | MAPK1, MAPK7, MAP3K1 | DDR2 3028/4885SRC 1387/4885GSK3A 1443/4885 |
| US-20080032967-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | MAPK1, MAPK8, MAPK4 | DDR2 3203/4885SRC 1394/4885GSK3A 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.